Skip to main content

ADC Therapeutics SA

corporate_fare Company Profile

ADC Therapeutics SA

ADCT·NYSE·Life Sciences·CIK 0001771910

ADC Therapeutics is a commercial-stage global company focused on antibody drug conjugates (ADCs). The company's primary product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA has received accelerated approval from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Commission, China National Medical Products Administration (NMPA), and Health Canada. It is approved for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ADC Therapeutics is expanding ZYNLONTA internationally and into earlier lines of DLBCL through the LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination). The company is also exploring ZYNLONTA's use in indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL), through investigator-initiated trials (IITs). Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics manages specialized capabilities spanning clinical development, manufacturing, and commercialization. The company completed IND-enabling activities for ADCT-241, an exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC, at the end of 2025. ADC Therapeutics utilizes its in-house chemistry, manufacturing and controls (CMC) capabilities and an external manufacturing network of third-party contract manufacturing organizations (CMOs) for highly potent molecules and complex biologics.

ADC Therapeutics SA (NYSE:ADCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ADCT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Board Seeks Shareholder Approval for Substantial Capital Range and Equity Plan Increases, Potentially Diluting Existing Shares by Over 70%
  • ADC Therapeutics Registers 9.83M Shares for Resale by Institutional Investor, Creating Potential Overhang
  • ADC Therapeutics Reports 2025 Financials, Details Restructuring, and Secures $150.7M in Private Placements
  • ADC Therapeutics Reports Strong Q4/FY25 Results, Extends Cash Runway, and Enhances M&A Flexibility
  • ADC Therapeutics Reports Strong Q4 Revenue, Positive LOTIS-7 Data, and Extends Cash Runway into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$81.36M
Net Income
-$142.62M
Diluted EPS
-$1.12
Op. Cash Flow
-$141.17M
Free Cash Flow
-$141.44M
Gross Profit
$75.56M
Operating Income
-$121.5M
Cash & Equivalents
$261.34M
Total Debt
$3M
Debt / Equity
-0.02×
Net Margin
-175.3%
Shares Outstanding
125.75M sh
Source: 10-K · filed 2026-03-10 · accession 0001628280-26-016491
$1.28
52-week range · as of 2026-11-09 $0.7796 – $4.98
Market cap
$180.05M
Volume
1.1M (0.8× avg)
3-mo avg 1.3M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADCT - Filings & News (Page 2)

ADCT
Apr 10, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $3.74
Real-time Price: $1.28 info
Change: -$2.46 (-66%) info
Market Cap: $180.047M info
ADCT
Mar 16, 2026, 5:02 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $1.28 info
Change: -$2.94 (-70%) info
Market Cap: $180.047M info
ADCT
Mar 10, 2026, 4:36 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.80
Real-time Price: $1.28 info
Change: -$3.52 (-73%) info
Market Cap: $180.047M info
ADCT
Mar 10, 2026, 7:58 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.34
Real-time Price: $1.28 info
Change: -$3.06 (-71%) info
Market Cap: $180.047M info
ADCT
Mar 10, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.23
Real-time Price: $1.28 info
Change: -$2.95 (-70%) info
Market Cap: $180.047M info
ADCT
Feb 23, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $1.28 info
Change: -$2.82 (-69%) info
Market Cap: $180.047M info
ADCT
Jan 12, 2026, 8:37 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $1.28 info
Change: -$2.48 (-66%) info
Market Cap: $180.047M info
ADCT
Jan 08, 2026, 5:04 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.57
Real-time Price: $1.28 info
Change: -$2.29 (-64%) info
Market Cap: $180.047M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets